ArticleCell division2025
Role of LINC00332 in colorectal cancer progression and paclitaxel resistance.
Article in Cell division, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is the third most common cancer and a leading cause of cancer deaths. Standard therapeutic management is faced with challenges like treatment resistance and late-stage diagnosis, highlighting a need for better diagnosis. LncRNAs are crucial in CRC progression and may serve as non-invasive biomarkers. For the first time, this study explores LINC00332 potential as a therapeutic and diagnostic marker in CRC.
methodsEighty fresh normal and tumor tissues were enrolled to evaluate the levels of LINC00332 expression using Real-time PCR method. LINC00332 ectopic expression was also done to evaluate its role in drug resistance and cell migration in HCT116 cells.
resultsEctopic expression of LINC00332 significantly induced NOTCH and WNT pathways in HCT116 cells. LINC00332 promoted EMT process through up regulation of Vimentin, CDH2, Snail, ZEB2, Slug, MMP10, and MMP3 while down regulation of CDH1 and OCLUDIN in HCT116 cells. LINC00332 significantly induced the HCT116 cell migration and paclitaxel (PTX) resistance in HCT116 cells (p < 0.0001). There was significant up regulation of LINC00332 in CRC clinical samples compared to normal margins (p = 0.042). There was significant up regulation of LINC00332 in stage I/II tumors that was located in transverse and left colon in comparison to right colon (p = 0.03). Tumors with perineural invasion had significant LINC00332 up regulation compared with negative ones in CRC patients (p = 0.02).
conclusionsLINC00332 promotes PTX resistance and EMT in CRC via WNT and NOTCH pathways activation. It can also be suggested as a potential diagnostic marker in early-stage CRC patients. Targeting LINC00332 may enhance PTX response, warranting further studies for therapeutic application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.